All In Biotech

Free tool

FAERS Monitor: Fetroja

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209445 or its brand name (Fetroja, Cefiderocol Sulfate Tosylate). Reports on generic versions are filed under their own applications.

Reports

315

Serious

282

90% of reports

Hospitalization

68

Death reported

147

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death71
  • drug resistance31
  • treatment failure27
  • off label use26
  • acute kidney injury23
  • pathogen resistance17
  • hepatic cytolysis14
  • multiple organ dysfunction syndrome14
  • infection13
  • cholestasis12
  • condition aggravated11
  • septic shock11
  • encephalopathy10
  • no adverse event10
  • chromaturia9

Reports by year received

View as table
YearReports
202011
202132
202271
202382
202468
202533
202618

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,844 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pathogen resistanceSignal17124.878.51,962
drug resistanceSignal3180.757.72,360
hepatic cytolysisSignal1473.444.0928
cholestasisSignal1241.824.0438
multiple organ dysfunction syndromeSignal1433.019.8404
encephalopathySignal1027.214.8227
chromaturiaSignal926.614.0197
treatment failureSignal2721.815.2516
septic shockSignal1116.99.4149
acute kidney injurySignal2310.06.8179
infectionSignal136.03.550
deathSignal715.54.5268
no adverse eventSignal103.72.017
condition aggravatedSignal112.41.48
off label use262.01.412

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.